MARKET

OVID

OVID

Ovid Therapeutics Inc
NASDAQ
3.120
+0.070
+2.30%
Opening 11:02 03/28 EDT
OPEN
3.060
PREV CLOSE
3.050
HIGH
3.120
LOW
3.040
VOLUME
20.22K
TURNOVER
0
52 WEEK HIGH
4.139
52 WEEK LOW
2.400
MARKET CAP
220.61M
P/E (TTM)
-4.2077
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at OVID last week (0318-0322)?
Weekly Report · 3d ago
Insider Buys Additional US$50k In Ovid Therapeutics Stock
Jeremy Levin, the President of Ovid Therapeutics Inc. Recently bought US$50k worth of shares at US$2.76 per share. It is the biggest insider purchase in the last year. The company's insider ownership of 5.2% of the company is good to see. Jeremy Levin was the only individual to buy shares in OvidTherapeutics over the last 12 months. You can see the insider transactions at Ovidtherapeutics in the table below. Ovid therapeutics is currently trading on the NASDAQ.
Simply Wall St · 6d ago
Over $2M Bet On NextNav? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Dow Jones index closed higher by over 400 points on Wednesday. Insider transactions for penny stocks indicate confidence or concern around the company's prospects. NextNav Inc. And Ovid Therapeutics Inc. Have recently had notable insider transactions for their shares. Eyenovia reported worse-than-expected fourth-quarter financial results.
Benzinga · 03/21 10:45
Weekly Report: what happened at OVID last week (0311-0315)?
Weekly Report · 03/18 09:20
Ovid Therapeutics: Strong Buy Rating on Robust Pipeline and Strategic Partnerships
TipRanks · 03/12 10:45
Institutional investors may overlook Ovid Therapeutics Inc.'s (NASDAQ:OVID) recent US$28m market cap drop as long-term gains remain positive
Institutional investors own 32% of Ovid Therapeutics Inc. (NASDAQ:OVID) The top 7 shareholders own 53% of the company. Takeda Pharmaceutical Company Limited is the largest shareholder with 11% of shares. OvidTherapeutics has a large amount of shares in the company, but the stock is vulnerable to insider selling. The company's ownership of 32% could be a concern for the company's future growth. It's also worth looking at the past earnings history of the firm.
Simply Wall St · 03/12 10:03
Ovid Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Ovid Therapeutics Inc reports results for the quarter ended in December. Revenue rose 206.8% to $142.00 thousand from a year ago. The company reported a quarterly adjusted loss of 22 cents per share. The mean expectation of seven analysts was for a loss of 5 cents.
Reuters · 03/11 13:32
Weekly Report: what happened at OVID last week (0304-0308)?
Weekly Report · 03/11 09:19
More
About OVID
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.

Webull offers Ovid Therapeutics Inc stock information, including NASDAQ: OVID real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OVID stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OVID stock methods without spending real money on the virtual paper trading platform.